1. The document discusses how drug companies have helped construct the medical condition of Female Sexual Dysfunction (FSD) by influencing its definition, inflating prevalence estimates, and developing diagnosis tools and education programs. 2. Studies finding higher prevalence of FSD have largely been funded by drug companies, while non-industry studies find lower rates. 3. Drugs to treat FSD conditions like Hypoactive Sexual Desire Disorder (HSDD) have not proven effective and may carry health risks, yet drug companies continue direct-to-consumer campaigns to promote "diseases" and treatments.

1. Building a social movement

2. MoDed: Building a social movement A presentation from a former sufferer of Motivational Deficiency Disorder, MoDed Ray Moynihan Past-president Unmotivated Anonymous Inc. Amsterdam, 2010

4. Motivational Deficiency Disorder

5. Motivational Deficiency Disorder

6. Motivational Deficiency Disorder

7. Motivational Deficiency Disorder

8. Motivational Deficiency Disorder

10. Sex, Lies & Pharmaceuticals Author & Journalist Ray Moynihan Visiting Editor British Medical Journal Amsterdam , 2010 www.raymoynihan.net

21. Global drug sales Billions source IMS, 2010 est. only

45. Pfizer survey

46. Pfizer Survey

49. Lacking interest in sex

52. P&G survey

53. P&G survey

56. Boehringer survey

57. Boehringer survey

63. How widespread is FSD?

71. Female Sexual Function Index 2000

72. Sexual Function Questionnaire 2002

80. Pfizer funded education

82. P&G funded education

88. CBS St Louis, May 2010

90. CNN Joy Behar, May 2010

92. WNBC NY , May 2010

99. This weeks BMJ

107. Selling Sickness – inflated claims * % of women. ** In any given year. All sources available from Ray Moynihan